Radioimmunotherapy with alpha-particles emitting radionuclides of cancer and infections

Ekaterina Dadachova (U Saskatchewan)
Event Date and Time: 
Thu, 2018-02-15 14:00 - 15:00
TRIUMF Auditorium

The use of targeted therapy with alpha particles emitters in oncology is burgeoning worldwide. This is driven by the advantages of alpha emitters over beta emitters, including very specific targeting of the diseased cells due to the alpha particles' short 50-80 micron tissue range, and increased killing efficiency due to high linear energy transfer. This results in a controlled therapeutic modality with minimal normal tissue effects. Radioimmunotherapy (RIT) with alpha emitters does not depend on the oxygenation status of the tumor, and alpha therapy can break tumor resistance to chemotherapy, external beam radiation therapy, and even to beta radiation therapy. In our laboratory we are investigating novel antigens and antibodies for using alpha RIT to treat melanoma and pancreatic cancer. Several years ago we were the first to translate alpha RIT approach into the field of infectious diseases for treatment of opportunistic fungal infections, multidrug resistant bacterial infections and HIV. The latest results of our pre-clinical work will be described.

Website development by Checkmark Media. Designed by Armada.

a place of mind, The University of British Columbia

Faculty of Science
Department of Physics and Astronomy
6224 Agricultural Road
Vancouver, BC V6T 1Z1
Tel 604.822.3853
Fax 604.822.5324

Emergency Procedures | Accessibility | Contact UBC | © Copyright The University of British Columbia